Suven Life Sciences Limited (NSE:SUVEN)
India
· Delayed Price · Currency is INR 141.20
+11.10 (8.53%)
Apr 24, 2025, 3:30 PM IST
Suven Life Sciences Revenue
Suven Life Sciences had revenue of 16.10M INR in the quarter ending December 31, 2024, a decrease of -34.31%. This brings the company's revenue in the last twelve months to 75.74M, down -36.75% year-over-year. In the fiscal year ending March 31, 2024, Suven Life Sciences had annual revenue of 116.93M, down -13.99%.
Revenue (ttm)
75.74M
Revenue Growth
-36.75%
P/S Ratio
405.40
Revenue / Employee
537.16K
Employees
141
Market Cap
30.70B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | 116.93M | -19.02M | -13.99% |
| Mar 31, 2023 | 135.95M | 16.44M | 13.76% |
| Mar 31, 2022 | 119.51M | -21.23M | -15.08% |
| Mar 31, 2021 | 140.73M | -6.32M | -4.30% |
| Mar 31, 2020 | 147.05M | -2.71B | -94.86% |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
| Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Suven Life Sciences News
- 3 months ago - Suven Life Sciences shares surge over 8% after clinical trial update - Business Upturn
- 3 months ago - Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107 - Business Upturn